Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2005 2
2006 4
2007 6
2008 3
2009 3
2010 6
2011 5
2012 3
2013 3
2014 6
2015 8
2016 6
2017 6
2018 8
2019 4
2020 12
2021 12
2022 17
2023 19
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for paolo zucali
Search for Paolo Zoccali instead (2 results)
Thymoma and thymic carcinomas.
Scorsetti M, Leo F, Trama A, D'Angelillo R, Serpico D, Macerelli M, Zucali P, Gatta G, Garassino MC. Scorsetti M, et al. Among authors: zucali p. Crit Rev Oncol Hematol. 2016 Mar;99:332-50. doi: 10.1016/j.critrevonc.2016.01.012. Epub 2016 Jan 19. Crit Rev Oncol Hematol. 2016. PMID: 26818050 Review.
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, Lo Russo G, Florescu M, Mencoboni M, Morabito A, Cecere FL, Ceresoli GL, Dawe DE, Zucali PA, Pagano M, Goffin JR, Sanchez ML, Gridelli C, Zalcman G, Quantin X, Westeel V, Gargiulo P, Delfanti S, Tu D, Lee CW, Leighl N, Sederias J, Brown-Walker P, Luo Y, Lantuejoul S, Tsao MS, Scherpereel A, Bradbury P, Laurie SA, Seymour L. Chu Q, et al. Among authors: zucali pa. Lancet. 2023 Dec 16;402(10419):2295-2306. doi: 10.1016/S0140-6736(23)01613-6. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931632 Clinical Trial.
Target Therapy in Malignant Pleural Mesothelioma: Hope or Mirage?
Borea F, Franczak MA, Garcia M, Perrino M, Cordua N, Smolenski RT, Peters GJ, Dziadziuszko R, Santoro A, Zucali PA, Giovannetti E. Borea F, et al. Among authors: zucali pa. Int J Mol Sci. 2023 May 23;24(11):9165. doi: 10.3390/ijms24119165. Int J Mol Sci. 2023. PMID: 37298116 Free PMC article. Review.
PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
Urso L, Filippi L, Castello A, Marzola MC, Bartolomei M, Cittanti C, Florimonte L, Castellani M, Zucali P, Bruni A, Sabbatini R, Dominici M, Panareo S, Evangelista L. Urso L, et al. Among authors: zucali p. J Clin Med. 2023 Nov 16;12(22):7130. doi: 10.3390/jcm12227130. J Clin Med. 2023. PMID: 38002742 Free PMC article. Review.
Thymic Epithelial Tumor and Immune System: The Role of Immunotherapy.
Perrino M, Cordua N, De Vincenzo F, Borea F, Aliprandi M, Cecchi LG, Fazio R, Airoldi M, Santoro A, Zucali PA. Perrino M, et al. Among authors: zucali pa. Cancers (Basel). 2023 Nov 25;15(23):5574. doi: 10.3390/cancers15235574. Cancers (Basel). 2023. PMID: 38067278 Free PMC article. Review.
Advances in drug treatments for mesothelioma.
Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Fazio R, Pirozzi A, Santoro A. Zucali PA, et al. Expert Opin Pharmacother. 2022 Jun;23(8):929-946. doi: 10.1080/14656566.2022.2072211. Epub 2022 May 9. Expert Opin Pharmacother. 2022. PMID: 35508368
Systemic treatments for thymic tumors: a narrative review.
Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Santoro A. Zucali PA, et al. Mediastinum. 2021 Sep 25;5:24. doi: 10.21037/med-21-11. eCollection 2021. Mediastinum. 2021. PMID: 35118329 Free PMC article. Review.
Imaging biomarkers in primary brain tumours.
Lopci E, Franzese C, Grimaldi M, Zucali PA, Navarria P, Simonelli M, Bello L, Scorsetti M, Chiti A. Lopci E, et al. Among authors: zucali pa. Eur J Nucl Med Mol Imaging. 2015 Apr;42(4):597-612. doi: 10.1007/s00259-014-2971-8. Epub 2014 Dec 18. Eur J Nucl Med Mol Imaging. 2015. PMID: 25520293 Review.
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study.
Zucali PA, Lin CC, Carthon BC, Bauer TM, Tucci M, Italiano A, Iacovelli R, Su WC, Massard C, Saleh M, Daniele G, Greystoke A, Gutierrez M, Pant S, Shen YC, Perrino M, Meng R, Abbadessa G, Lee H, Dong Y, Chiron M, Wang R, Loumagne L, Lépine L, de Bono J. Zucali PA, et al. J Immunother Cancer. 2022 Jan;10(1):e003697. doi: 10.1136/jitc-2021-003697. J Immunother Cancer. 2022. PMID: 35058326 Free PMC article. Clinical Trial.
hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC.
Trono P, Tocci A, Palermo B, Di Carlo A, D'Ambrosio L, D'Andrea D, Di Modugno F, De Nicola F, Goeman F, Corleone G, Warren S, Paolini F, Panetta M, Sperduti I, Baldari S, Visca P, Carpano S, Cappuzzo F, Russo V, Tripodo C, Zucali P, Gregorc V, Marchesi F, Nistico P. Trono P, et al. Among authors: zucali p. J Immunother Cancer. 2023 Aug;11(8):e006913. doi: 10.1136/jitc-2023-006913. J Immunother Cancer. 2023. PMID: 37612043 Free PMC article.
126 results